Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
Eyre TA, Osborne WL, Gallop-Evans E, Ardeshna KM, Kassam S, Sadullah S, Sidra G, Culligan D, Arumainathan A, Shankara P, Bowles KM, Eyre DW, Peng YY, Pettengell R, Bloor A, Vandenberghe E, Collins GP. Eyre TA, et al. Among authors: shankara p. Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24. Br J Haematol. 2018. PMID: 28342183 Free article. Clinical Trial. No abstract available.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS. Eyre TA, et al. Among authors: shankara p. Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9. Br J Haematol. 2016. PMID: 26956150 Free article.
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Eyre TA, Fox CP, Boden A, Bloor A, Dungawalla M, Shankara P, Went R, Schuh AH. Eyre TA, et al. Among authors: shankara p. Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22. Br J Haematol. 2019. PMID: 29468637 Free article. Clinical Trial. No abstract available.
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, Cross M, Forconi F, Shah N, Chasty R, Hart A, Broom A, Marr H, Patten PEM, Dann A, Arumainathan A, Munir T, Shankara P, Bloor A, Johnston R, Orchard K, Schuh AH, Fox CP; the UK CLL Forum. Eyre TA, et al. Among authors: shankara p. Br J Haematol. 2019 May;185(4):656-669. doi: 10.1111/bjh.15802. Epub 2019 Feb 15. Br J Haematol. 2019. PMID: 30768675 Free article.
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
Horgan C, Elmoamly S, McIlroy G, Davies D, Kaparou M, Giles H, Xenou E, Kishore B, Lovell R, Nikolousis E, Shankara P, Kanellopoulos A. Horgan C, et al. Among authors: shankara p. Leuk Lymphoma. 2019 Dec;60(12):3075-3077. doi: 10.1080/10428194.2019.1607323. Epub 2019 May 13. Leuk Lymphoma. 2019. PMID: 31079514 No abstract available.
Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc SN, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede LC, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P. Schetelig J, et al. Among authors: shankara p. Bone Marrow Transplant. 2021 Mar;56(3):605-613. doi: 10.1038/s41409-020-01069-w. Epub 2020 Oct 2. Bone Marrow Transplant. 2021. PMID: 33004942 Free PMC article.
Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
McIlroy G, Nikolousis E, Abou-Zeid N, Shankara P, Kishore B, Kaparou M, Lovell R, Elmoamly S, Davies D, Horgan C, Shenouda A, Kanellopoulos A. McIlroy G, et al. Among authors: shankara p. Leuk Lymphoma. 2020 Jan;61(1):202-205. doi: 10.1080/10428194.2019.1650177. Epub 2019 Aug 11. Leuk Lymphoma. 2020. PMID: 31402762 No abstract available.
Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center.
Lloyd R, Nikolousis E, Kishore B, Lovell R, Shankara P, Zeid NA, Horgan C, Panteliadou AK, McIlroy G, Xenou E, Kaparou M, Holder K, Murthy V, Kanellopoulos A. Lloyd R, et al. Among authors: shankara p. Cell Transplant. 2020 Jan-Dec;29:963689720950641. doi: 10.1177/0963689720950641. Cell Transplant. 2020. PMID: 32806929 Free PMC article.
First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Horgan C, Kartsios C, Nikolousis E, Shankara P, Kishore B, Lovell R, Murthy V, Rudzki Z, Dyer S, Holtom P, Thompson G, Kaparou M, Xenou E, Lloyd R, Venkatadasari I, Kanellopoulos AG. Horgan C, et al. Among authors: shankara p. Leuk Res Rep. 2020 Jun 18;14:100213. doi: 10.1016/j.lrr.2020.100213. eCollection 2020. Leuk Res Rep. 2020. PMID: 32612922 Free PMC article.
11 results